Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 178   

Articles published

AZN 4,500.00 +56.00 (1.26%)
price chart
What Happens If Pfizer Inc. Doesn't Come Back For AstraZeneca plc?
Since May, AstraZeneca's (LSE: AZN) (NYSE: AZN.US) shareholders have been excitedly awaiting the return of Pfizer to make a new buyout offer for the UK's second largest pharmaceutical company.
GlaxoSmithKline PLC vs AstraZeneca PLC: Which Is The Better Dividend Play?  Yahoo Finance UK
Overheard: Astra's Payout Pipeline  Wall Street Journal
Related articles »  
Is Now The Right Time To Buy AstraZeneca plc?
After all, AstraZeneca's share price has fallen by 6% since 23 September, when changes to US tax rules made a bid less financially attractive for US companies.
Related articles »  
Why You Should Let AstraZeneca plc Look After Your Money
I recently made a trip to my local GP. I was suffering from a common skin infection. Three trips later, and after I had purchased multiple creams and ointments, the infection began to clear.
AstraZeneca's Diabetes Treatment Xigduo XR Wins FDA Approval
AstraZeneca plc (ADR) (AZN) announced Thursday morning that it has received the US Food and Drug Administration's approval for its experimental drug Xigduo XR as a �daily treatment for type 2 diabetes� for individuals 18 years of age or older.
US FDA Approves AstraZeneca Type 2 Diabetes Treatment Xigduo XR  London South East
Astrazeneca Receives US FDA Approval For Type-2 Diabetes Drug XIGDUO XR  RTT News
Related articles »  
Is AstraZeneca plc A Promising Capital-Growth Investment?
astrazeneca2 The pharmaceutical industry continues to attract for its 'defensive' qualities and AstraZeneca (LSE: AZN) (NYSE: AZN.
AstraZeneca plc Assigned AA- Credit Rating (AZN)
AstraZeneca plc (NYSE:AZN) has earned an �AA-� credit rating from analysts at Morningstar. The research firm's �AA-� rating indicates that the company is a very-low default risk.
Stocks in the News -AstraZeneca plc (ADR) (NYSE:AZN), Rosetta Resources Inc ...  Techsonian (press release)
Related articles »  
Why I'd Still Buy AstraZeneca plc Despite Shire PLC Deal Collapse
A key reason for such strong gains has been continued bid rumours for the business, following three firm offers from sector peer Pfizer.
Related articles »  
Why Have GlaxoSmithKline plc And AstraZeneca plc Followed The FTSE 100 ...
Investors tend to turn to big blue-chip dividend payers at times of market volatility, and in times past the steady earnings of pharma giants GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) have been a particular source of comfort when the market ...
Related articles »  
Why Smith & Nephew plc's Latest Failure Should Worry AstraZeneca plc And ...
Medical play Smith and Nephew (LSE: SN) disappointed the market on Monday when it announced that testing of its GlaxoSmithKline HP802-247 treatment in North America - a spray designed to treat veinous leg ulcers (or VLUs) - had failed at the Phase ...
Why I'd Sell AstraZeneca plc And Buy Shire PLC
Shire (LSE: SHP) and AstraZeneca (LSE: AZN) are two very different companies. On one hand, Shire is growing rapidly and has plenty of new drugs under development, which should drive sales growth.